Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management-Reference-Cited by-同舟云学术

Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management

Published:2024-05-20 Issue:8 Volume:99 Page:1586-1594
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Ramirez‐Gamero Andres¹^ORCID,Martínez‐Cordero Humberto²^ORCID,Beltrán Brady E.³^ORCID,Florindez Jorge⁴^ORCID,Malpica Luis⁵^ORCID,Castillo Jorge J.¹⁶^ORCID

Affiliation:

1. Division of Hematologic Malignancies Dana‐Farber Cancer Institute Boston Massachusetts USA

2. Instituto Nacional de Cancerologia and Hospital Militar Central Bogota Colombia

3. Department of Oncology and Radiotherapy, Hospital Edgardo Rebagliati Martins and Instituto de Ciencias Biomedicas Universidad Ricardo Palma Lima Peru

4. Division of Hematology and Oncology University of North Carolina Chapel Hill North Carolina USA

5. Department of Lymphoma and Myeloma University of Texas MD Anderson Cancer Center Houston Texas USA

6. Department of Medicine Harvard Medical School Boston Massachusetts USA

Abstract

AbstractDisease OverviewPlasmablastic lymphoma (PBL) is a rare CD20‐negative aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL is associated with human immunodeficiency virus infection and other immunosuppressed states, it can also affect immunocompetent individuals.DiagnosisThe diagnosis requires a high clinical suspicion and pathological confirmation. EBER expression and MYC gene rearrangements are frequently detected. The differential diagnosis includes EBV+ diffuse large B‐cell lymphoma, extracavitary primary effusion lymphoma, ALK+ DLBCL, and HHV8+ large B‐cell lymphoma, among others.Risk StratificationAge ≥60 years, advanced clinical stage, and high intermediate and high International Prognostic Index scores are associated with worse survival.ManagementCombination chemotherapy regimens, such as EPOCH, are recommended. The addition of bortezomib, lenalidomide, or daratumumab might improve outcomes. Including PBL patients and their participation in prospective clinical trials is warranted.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27376

Reference78 articles.

1. Plasmablastic Lymphomas of the Oral Cavity: A New Entity Associated With the Human Immunodeficiency Virus Infection

2. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base

3. HIV-Negative Plasmablastic Lymphoma: Not in the Mouth

4. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients